MY203654A - Gene therapy for retinitis pigmentosa - Google Patents

Gene therapy for retinitis pigmentosa

Info

Publication number
MY203654A
MY203654A MYPI2020002274A MYPI2020002274A MY203654A MY 203654 A MY203654 A MY 203654A MY PI2020002274 A MYPI2020002274 A MY PI2020002274A MY PI2020002274 A MYPI2020002274 A MY PI2020002274A MY 203654 A MY203654 A MY 203654A
Authority
MY
Malaysia
Prior art keywords
retinitis pigmentosa
gene therapy
viral particles
particles
mutants
Prior art date
Application number
MYPI2020002274A
Other languages
English (en)
Inventor
Matthew Adamowicz
Catherine O'riordan
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52829343&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY203654(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MY203654A publication Critical patent/MY203654A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MYPI2020002274A 2014-03-21 2015-03-20 Gene therapy for retinitis pigmentosa MY203654A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461969027P 2014-03-21 2014-03-21
PCT/US2015/021896 WO2015143418A2 (en) 2014-03-21 2015-03-20 Gene therapy for retinitis pigmentosa

Publications (1)

Publication Number Publication Date
MY203654A true MY203654A (en) 2024-07-11

Family

ID=52829343

Family Applications (2)

Application Number Title Priority Date Filing Date
MYPI2020002274A MY203654A (en) 2014-03-21 2015-03-20 Gene therapy for retinitis pigmentosa
MYPI2016703077A MY190726A (en) 2014-03-21 2015-03-20 Gene therapy for retinitis pigmentosa

Family Applications After (1)

Application Number Title Priority Date Filing Date
MYPI2016703077A MY190726A (en) 2014-03-21 2015-03-20 Gene therapy for retinitis pigmentosa

Country Status (36)

Country Link
US (3) US10383953B2 (enExample)
EP (3) EP4345165A3 (enExample)
JP (3) JP6669664B2 (enExample)
KR (3) KR20160127832A (enExample)
CN (2) CN106456660B (enExample)
AR (1) AR099837A1 (enExample)
AU (3) AU2015230942B2 (enExample)
CA (2) CA2943185C (enExample)
CL (1) CL2016002333A1 (enExample)
CR (1) CR20160480A (enExample)
DK (2) DK3628334T5 (enExample)
DO (1) DOP2016000237A (enExample)
EA (1) EA201691891A1 (enExample)
EC (1) ECSP16083000A (enExample)
ES (2) ES2957840T3 (enExample)
FI (1) FI3628334T3 (enExample)
HR (2) HRP20192141T1 (enExample)
HU (2) HUE046454T2 (enExample)
IL (3) IL247543B (enExample)
LT (2) LT3119437T (enExample)
MA (1) MA39390B2 (enExample)
MX (2) MX376190B (enExample)
MY (2) MY203654A (enExample)
NZ (1) NZ724622A (enExample)
PE (1) PE20161252A1 (enExample)
PH (1) PH12016501684B1 (enExample)
PL (2) PL3628334T3 (enExample)
PT (2) PT3119437T (enExample)
RS (2) RS59634B1 (enExample)
SG (3) SG10201912968WA (enExample)
SI (2) SI3119437T1 (enExample)
TW (2) TWI780401B (enExample)
UA (1) UA120050C2 (enExample)
UY (1) UY36044A (enExample)
WO (1) WO2015143418A2 (enExample)
ZA (1) ZA201605924B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA120050C2 (uk) 2014-03-21 2019-09-25 Джензайм Корпорейшн Генна терапія для лікування пігментного ретиніту
JP2018506304A (ja) 2015-02-10 2018-03-08 ジェンザイム・コーポレーション バリアントＲＮＡｉ
US10994026B2 (en) 2015-12-03 2021-05-04 Friedrich Miescher Institute For Biomedical Research SynP160, a promoter for the specific expression of genes in rod photoreceptors
CN108472390B (zh) 2015-12-03 2022-04-15 弗里德里克·米谢尔生物医学研究所 SynP162,用于基因在视杆光感受器中特异性表达的启动子
ES2872798T3 (es) * 2015-12-04 2021-11-02 Univ Sorbonne Promotores y usos de los mismos
IL261014B2 (en) 2016-03-01 2023-10-01 Univ Florida Aav vectors for treatment of dominant retinitis pigmentosa
SG11201900049QA (en) * 2016-07-05 2019-02-27 Univ Johns Hopkins Crispr/cas9-based compositions and methods for treating retinal degenerations
UY37636A (es) * 2017-03-21 2018-10-31 Univ Muenchen Ludwig Maximilians Terapia génica para el tratamiento de retinitis pigmentosa ligada a cngb1
CN111356763B (zh) * 2017-09-22 2024-03-12 建新公司 变体RNAi
BR112020006149A2 (pt) * 2017-09-27 2020-10-20 Sigilon Therapeutics, Inc. célula ativa manipulada, elemento implantável, e, composição farmacêutica.
CN107961380B (zh) * 2017-11-23 2020-05-05 清华大学 试剂在制备药物中的用途、筛选药物的方法以及药物组合物
WO2019169245A1 (en) 2018-03-02 2019-09-06 Sigilon Therapeutics, Inc. Biocompatible hydrogel capsules and process for preparing same
WO2019183630A2 (en) * 2018-03-23 2019-09-26 The Trustees Of Columbia University In The City Of New York Gene editing for autosomal dominant diseases
US12161760B2 (en) 2018-04-04 2024-12-10 Sigilon Therapeutics, Inc. Implantable particles and related methods
US12203074B2 (en) 2018-06-01 2025-01-21 University Of Florida Research Foundation, Incorporated Compositions and methods for treatment of dominant retinitis pigmentosa
GB201817469D0 (en) * 2018-10-26 2018-12-12 Univ Oxford Innovation Ltd Gene therapy for retinal disease
CN111518813B (zh) * 2019-02-03 2023-04-28 武汉纽福斯生物科技有限公司 视紫红质的编码序列、其表达载体构建及其应用
EP3934699A4 (en) 2019-03-04 2022-12-21 The Trustees of The University of Pennsylvania NEUROPROTECTIVE GENE THERAPY TARGETING THE AKT PATHWAY
MX2021011198A (es) * 2019-03-21 2022-03-04 Ptc Therapeutics Inc Vector y método para tratar el síndrome de angelman.
WO2021030745A1 (en) * 2019-08-15 2021-02-18 The Children's Hospital Of Philadelphia Combined transgene and intron-derived mirna therapy for treatment of sca1
CN115279421A (zh) * 2020-01-10 2022-11-01 坚固生物科技公司 用于联合疗法的病毒载体
KR20220133941A (ko) * 2020-01-29 2022-10-05 젠자임 코포레이션 안과 유전자 치료를 위한 변형 아데노-관련 바이러스 캡시드 단백질 및 이의 사용 방법
EP4071247A4 (en) * 2020-07-24 2023-08-23 Rznomics Inc. TRANSSPLICING OF RIBOZYME SPECIFIC TO RHODOPSIN TRANSCRIPTOME AND ITS USE
CA3190214A1 (en) * 2020-07-29 2022-02-03 University Of Florida Research Foundation, Incorporated Improved aav-mediated x-linked retinoschisis therapies
WO2022221405A1 (en) * 2021-04-16 2022-10-20 Regeneron Pharmaceuticals, Inc. Treatment of x-linked juvenile retinoschisis
TWI832531B (zh) * 2022-11-02 2024-02-11 慈濟學校財團法人慈濟大學 Rip1抑制劑或mlkl抑制劑用於治療或預防遺傳性視網膜失養症的用途
CN117625619B (zh) * 2023-12-05 2024-11-12 云舟生物科技(广州)股份有限公司 核酸分子及其作为特异启动子的应用
CN120230798A (zh) * 2023-12-29 2025-07-01 上海朗昇生物科技有限公司 用于视网膜基因递送的重组腺相关病毒载体及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262529A (en) * 1990-01-24 1993-11-16 President And Fellows Of Harvard College Diagnosis of hereditary retinal degenerative diseases
US5985583A (en) * 1992-06-23 1999-11-16 Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of gonadotropin-releasing hormone receptor
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
ES2308989T3 (es) 1999-08-09 2008-12-16 Targeted Genetics Corporation Aumento de la expresion de una secuencia nucleotidica heterologa a partir de vectores viricos recombinantes que contienen una secuencia que forman pares de bases intracatenarios.
WO2001092551A2 (en) 2000-06-01 2001-12-06 University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
JP4677187B2 (ja) 2001-11-13 2011-04-27 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 新規なアデノ随伴ウイルス（ａａｖ）７配列、それを含むベクターおよびそれらの使用
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
WO2005071092A1 (ja) * 2004-01-22 2005-08-04 Dnavec Research Inc. サイトメガロウイルスエンハンサーおよびニワトリβ-アクチンプロモーターを含むハイブリッドプロモーターを利用したマイナス鎖RNAウイルスベクターの製造方法
US7765583B2 (en) 2005-02-28 2010-07-27 France Telecom System and method for managing virtual user domains
WO2006119432A2 (en) 2005-04-29 2006-11-09 The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes
WO2007120542A2 (en) 2006-03-30 2007-10-25 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid library and aav capsid proteins
ES2907452T3 (es) * 2007-04-12 2022-04-25 The Provost Fellows Found Scholars & The Other Members Of Board Of The College Of The Holy & Undiv T Supresión y reemplazo genético
US20090214478A1 (en) * 2008-02-21 2009-08-27 Alberto Auricchio Method of treating ocular diseases by gene therapy
US9217155B2 (en) * 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
WO2010138263A2 (en) * 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
CA2773619C (en) * 2009-09-10 2019-11-12 Svend Lindenberg Method for the preparation of micro-rna and its therapeutic application
CN102947453A (zh) 2010-01-28 2013-02-27 费城儿童医院 用于病毒载体纯化的可扩缩生产平台和用于基因治疗中的如此纯化的病毒载体
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
CN103189507A (zh) 2010-10-27 2013-07-03 学校法人自治医科大学 用于向神经系统细胞导入基因的腺相关病毒粒子
SG10201601110VA (en) 2011-02-17 2016-03-30 Univ Pennsylvania Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer
JP5884152B2 (ja) 2011-07-29 2016-03-15 シャープ株式会社 基地局、端末、通信システムおよび通信方法
ITRM20110685A1 (it) * 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
US20150111955A1 (en) * 2012-02-17 2015-04-23 The Children's Hospital Of Philadelphia Aav vector compositions and methods for gene transfer to cells, organs and tissues
HK1206779A1 (en) * 2012-04-02 2016-01-15 Modernatx, Inc. Modified polynucleotides for the production of nuclear proteins
US9127274B2 (en) * 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
PT3241902T (pt) * 2012-05-25 2018-05-28 Univ California Métodos e composições para modificação de adn alvo dirigida por arn e para modulação dirigida por arn de transcrição
US9770491B2 (en) 2012-07-11 2017-09-26 The Trustees Of The University Of Pennsylvania AAV-mediated gene therapy for RPGR X-linked retinal degeneration
CA2889020A1 (en) * 2012-10-23 2014-05-01 Cornell University Treatment of metastatic breast cancer
BR112016007176A2 (pt) 2013-10-04 2018-01-23 Merck Sharp & Dohme conjugado, composição, usos de um conjugado e de uma composição, e, método para tratar um indivíduo que tem diabete
UA120050C2 (uk) 2014-03-21 2019-09-25 Джензайм Корпорейшн Генна терапія для лікування пігментного ретиніту

Also Published As

Publication number Publication date
PH12016501684B1 (en) 2023-03-17
CA3254798A1 (en) 2025-12-01
HUE046454T2 (hu) 2020-03-30
ECSP16083000A (es) 2017-02-24
AU2021200988A1 (en) 2021-03-11
US20220054657A1 (en) 2022-02-24
AR099837A1 (es) 2016-08-24
US11103598B2 (en) 2021-08-31
KR20230006039A (ko) 2023-01-10
JP2022084810A (ja) 2022-06-07
US20200046851A1 (en) 2020-02-13
CN106456660B (zh) 2022-05-31
CN106456660A (zh) 2017-02-22
EP4345165A3 (en) 2024-09-25
MX376190B (es) 2025-03-07
IL275918A (en) 2020-08-31
IL284741B (en) 2022-10-01
US10383953B2 (en) 2019-08-20
TWI706789B (zh) 2020-10-11
MY190726A (en) 2022-05-12
PL3119437T3 (pl) 2020-04-30
UY36044A (es) 2015-10-30
IL284741B2 (en) 2023-02-01
EP3628334A1 (en) 2020-04-01
IL284741A (en) 2021-08-31
AU2015230942B2 (en) 2020-11-19
RS64611B1 (sr) 2023-10-31
HUE063460T2 (hu) 2024-01-28
RS59634B1 (sr) 2020-01-31
KR20250172735A (ko) 2025-12-09
TW202021627A (zh) 2020-06-16
JP2020059737A (ja) 2020-04-16
IL275918B (en) 2021-07-29
CA2943185A1 (en) 2015-09-24
SI3119437T1 (sl) 2020-01-31
AU2015230942A1 (en) 2016-10-13
IL247543B (en) 2020-07-30
SI3628334T1 (sl) 2023-11-30
CR20160480A (es) 2016-12-14
PT3119437T (pt) 2019-12-12
HRP20231077T1 (hr) 2023-12-22
DK3119437T3 (da) 2019-12-09
AU2021200988B2 (en) 2024-08-01
KR20160127832A (ko) 2016-11-04
CA2943185C (en) 2025-09-16
SG10201808218YA (en) 2018-10-30
MX2020010694A (es) 2020-11-06
CN115252823A (zh) 2022-11-01
JP7534348B2 (ja) 2024-08-14
HRP20192141T1 (hr) 2020-02-21
DOP2016000237A (es) 2016-10-16
MX2016012201A (es) 2017-01-19
EA201691891A1 (ru) 2017-01-30
DK3628334T3 (da) 2023-10-02
DK3628334T5 (da) 2024-09-02
MA39390B2 (fr) 2022-04-29
WO2015143418A2 (en) 2015-09-24
AU2024227776A1 (en) 2024-11-28
ES2760263T3 (es) 2020-05-13
UA120050C2 (uk) 2019-09-25
PE20161252A1 (es) 2016-11-30
JP2017509632A (ja) 2017-04-06
BR112016021017A2 (pt) 2017-10-03
NZ724622A (en) 2022-05-27
CL2016002333A1 (es) 2017-05-26
PL3628334T3 (pl) 2023-12-18
JP6669664B2 (ja) 2020-03-18
WO2015143418A3 (en) 2015-11-19
PT3628334T (pt) 2023-09-26
EP4345165A2 (en) 2024-04-03
SG10201912968WA (en) 2020-02-27
US12201698B2 (en) 2025-01-21
LT3628334T (lt) 2023-09-25
TW201622752A (zh) 2016-07-01
TWI780401B (zh) 2022-10-11
JP7048563B2 (ja) 2022-04-05
ES2957840T3 (es) 2024-01-26
SG11201607005UA (en) 2016-09-29
MA39390A1 (fr) 2017-12-29
EP3119437B1 (en) 2019-09-04
LT3119437T (lt) 2019-12-27
NZ762841A (en) 2023-11-24
ZA201605924B (en) 2017-09-27
FI3628334T3 (fi) 2023-09-15
IL247543A0 (en) 2016-11-30
EP3628334B1 (en) 2023-06-28
US20170173183A1 (en) 2017-06-22
PH12016501684A1 (en) 2016-10-03
EP3119437A2 (en) 2017-01-25

Similar Documents

Publication Publication Date Title
MX2020010694A (es) Particulas de raav que codifican mir-708 y usos del mismo.
MX2018005286A (es) Constructo genetico.
MX2021006581A (es) Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
MX2022000085A (es) Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad.
EP4344741A3 (en) Aav vectors targeted to the central nervous system
EA201891192A1 (ru) Средства и способы лечения миопатий, связанных с титином, и других титинопатий
MX2018005107A (es) Composiciones y metodos para la terapia relacionada con la microbiota fecal.
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
GB201403260D0 (en) Treatment of retinal degeneration using gene therapy
EP4094780A3 (en) Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
ZA201701881B (en) Adeno-associated viral vectors for treating myocilin (myoc) glaucoma
EP3998341A3 (en) Adenoviral vectors
WO2016106458A8 (es) Virus aav/xbp1s-ha, método de tratamiento genético y su uso en la optimización y mejoramiento de las capacidades cognitivas, de memoria y de aprendizaje
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
EP3738559B8 (de) System zur augentherapie mittels gewebebearbeitung durch nichtlineare wechselwirkung
PH12018501045A1 (en) Treatment of retinal degeneration using progenitor cells
PH12016501347A1 (en) Filters for infusion sets
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
UA104615U (uk) Спосіб лікування токсокарозу
HK40007440A (en) Gene therapy for treating hemophilia b
MX2015007650A (es) Tratamiento de retinitis pigmentosa.